HOXA9 and leukemia: Our orthogonal treatment results, based on both shRNA-mediated knockdown and pharmacological inhibition of Syk, showed that Hoxa9/Meis1-transformed leukemias were clearly more sensitive to Syk inhibition than Hoxa9-transformed leukemias.